Laurence Cooper Net Worth

The estimated Net Worth of Laurence James Neil Cooper is at least $5.71 Million dollars as of 4 January 2021. Laurence Cooper owns over 105,693 units of Alaunos Therapeutics Inc stock worth over $1,565,374 and over the last 10 years he sold ZIOP stock worth over $826,615. In addition, he makes $3,317,570 as Chief Executive Officer and Director at Alaunos Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Laurence Cooper ZIOP stock SEC Form 4 insiders trading

Laurence has made over 3 trades of the Alaunos Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 105,693 units of ZIOP stock worth $286,428 on 4 January 2021.

The largest trade he's ever made was selling 110,694 units of Alaunos Therapeutics Inc stock on 27 December 2019 worth over $540,187. On average, Laurence trades about 14,855 units every 77 days since 2015. As of 4 January 2021 he still owns at least 1,799,280 units of Alaunos Therapeutics Inc stock.

You can see the complete history of Laurence Cooper stock trades at the bottom of the page.

Laurence Cooper biography

Dr. Laurence James Neil Cooper M.D., Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Cooper has served as our Chief Executive Officer since May 2015 and as a director since October 2018. Prior to joining us, Dr. Cooper led the Pediatric Cell Therapy service (formally named the bone marrow transplantation (“BMT”) program) as a tenured professor at the University of Texas M.D. Anderson Cancer Center (“MD Anderson”), where he had worked since 2006. In addition to caring for children, adolescents and young adults undergoing autologous and allogeneic BMT at MD Anderson, he led a laboratory translating immunology into clinical practice. This program had multiple investigator-initiated trials that infused T cells and NK cells to target malignancies. Dr. Cooper also holds an appointment as a Visiting Scientist at MD Anderson. Dr. Cooper obtained his B.A. at Kenyon College in Gambier, Ohio and M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland before training in Pediatric Oncology and BMT at the Fred Hutchinson Cancer Research Center in Seattle. The board believes that Dr. Cooper’s insight into our operations and strategy as a result of being our Chief Executive Officer, and his scientific expertise and industry background qualifies him to serve on the board.

What is the salary of Laurence Cooper?

As the Chief Executive Officer and Director of Alaunos Therapeutics Inc, the total compensation of Laurence Cooper at Alaunos Therapeutics Inc is $3,317,570. There are no executives at Alaunos Therapeutics Inc getting paid more.

How old is Laurence Cooper?

Laurence Cooper is 55, he's been the Chief Executive Officer and Director of Alaunos Therapeutics Inc since 2018. There are 8 older and 7 younger executives at Alaunos Therapeutics Inc. The oldest executive at Alaunos Therapeutics Inc is J. Kevin Buchi, 65, who is the Director.

What's Laurence Cooper's mailing address?

Laurence's mailing address filed with the SEC is C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG. 34, BOSTON, MA, 02129.

Insiders trading at Alaunos Therapeutics Inc

Over the last 19 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk, and Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.

What does Alaunos Therapeutics Inc do?

Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.

Complete history of Laurence Cooper stock trades at Alaunos Therapeutics Inc

Alaunos Therapeutics Inc executives and stock owners

Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include:

• Laurence Cooper,
  Chief Executive Officer, Director
• Satyavrat Shukla,
  Chief Financial Officer
• Robert Hadfield,
  Executive Vice President, Chief Compliance Officer, General Counsel, Secretary
• Kevin Lafond,
  Senior Vice President - Finance, Chief Accounting Officer, Treasurer
• Heidi Hagen,
  Independent Director
• Dr. Eleanor de Groot Ph.D.,
  Exec. VP of Operations
• Christopher Bowden,
  Independent Director
• Scott Tarriff,
  Independent Chairman of the Board
• Dr. Raffaele Baffa M.D., Ph.D.,
  Chief Medical Officer and Exec. VP of R&D
• Elan Ezickson,
  Independent Director
• Zuie-Chin Huang M.B.A.,
  Exec. Chairman
• Mary Thistle,
  Independent Director
• Raffaele Baffa,
  Chief Medical Officer
• Christopher Taylor,
  Vice President, Investor Relations and Corporate Communications
• James Huang,
  Director
• J. Kevin Buchi,
  Director
• Lynn Ferrucci,
  Executive Vice President of Human Resources, Facilities, Administration and IT
• Eleanor De Groot,
  Executive Vice President, General Manager, Cell Therapy
• Jill Buck,
  Executive Vice President, General Manager, Gene Therapy
• Dr. Drew Deniger,
  Head of TCR-T Cell Therapy Program
• Dr. David M. Mauney M.D.,
  Consultant
• Melinda Lackey,
  Sr. VP of Legal
• Michael Wong,
  VP of Fin. & Principal Accounting Officer
• Timothy M. Cunningham CPA, M.B.A.,
  Interim CFO & Principal Financial Officer
• Kevin S. Boyle Sr.,
  CEO & Director
• James Anthony Cannon,
  Director
• Randal Jintrexon Corp Kirk,
  
• Murray Brennan,
  Director
• Wyche Fowler,
  Director
• Randal J Kirk,
  Director
• Caesar J Belbel,
  COO, CLO, and Secretary
• Michael Weiser,
  Director
• Francois Lebel,
  Executive Vice President R&D
• David M Md Mauney,
  President
• Douglas W. Pagan,
  Director
• Scott Braunstein,
  Director
• Hagop Youssoufian,
  Executive VP, CMO
• Timothy Mcinerney,
  Director
• Jonathan Lewis,
  CEO
• Jason Amello,
  Executive Vice President & CFO
• Richard E Bagley,
  President, COO & Treasurer
• George B Abercrombie,
  Director
• Robert Peter Gale,
  Senior V.P. of Research
• Lindsay A Md Rosenwald,
  10% owner
• Woodlands Health Ventures F...,
  10% owner
• Gary S Fragin,
  Director
• Sath Shukla,
  EVP, Chief Financial Officer
• Jaime Vieser,
  Director
• Holger Weis,
  Director
• Robert W Postma,
  Director
• Kevin S. Sr. Boyle,
  Chief Executive Officer
• Melinda Lackey,
  Senior Vice President, Legal